FAKTOR-OPTIONSSCHEIN - NOVO-NORDISK B | Market Closed - Deutsche Boerse AG 20:45:33 24/05/2024 BST | ||
| 0.61 EUR | 0.00% |
|
| Current month | -12.86% | ||
| 1 month | -18.67% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
More news
| Date | Price | Change |
|---|---|---|
| 24/05/24 | 0.61 | 0.00% |
| 23/05/24 | 0.61 | -3.17% |
| 22/05/24 | 0.63 | +1.61% |
| 21/05/24 | 0.62 | -4.62% |
| 20/05/24 | 0.65 | -4.41% |
Delayed Quote Deutsche Boerse AG
Last update May 24, 2024 at 08:45 pm
More quotesStatic data
| Product type | Exotic Products |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVO NORDISK A/S |
| Issuer | 
Société Générale
|
| WKN | SQ628B |
| ISIN | DE000SQ628B7 |
| Date issued | 09/01/2023 |
| Strike | 958.5 kr |
| Maturity | Unlimited |
| Parity | 1 : 1 |
| Emission price | 10.13 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 12.24 € |
|---|---|
| Lowest since issue | 0.59 € |
| Spread | 0.01 € |
| Spread % | 1.61% |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
928.8
DKK
Average target price
909.2
DKK
Spread / Average Target
-2.11%
- Stock Market
- Certificates
- Certificat
